' fill='%23ffffff'%3E%3Cpath d='M283.94,167.31l386.39,516.64L281.5,1104h87.51l340.42-367.76L984.48,1104h297.8L874.15,558.3l361.92-390.99 h-87.51l-313.51,338.7l-253.31-338.7H283.94z M412.63,231.77h136.81l604.13,807.76h-136.81L412.63,231.77z'%3E%3C/path%3E%3C/g%3E%3C/svg%3E%0A){kind=small}
This section provides information on the latest news from NHS Research Scotland. You can also subscribe to Research Bulletin, our monthly newsletter, by accessing our subscribe form.
All media enquiries should be directed to Fiona Fleming, Communications Manager on 07549891564 or fiona.fleming@nrs.org.uk.
Chief Scientist Office Festive Message 2021
21st December 2021
Euan Dick, Head of the Chief Scientist Office (CSO) reflects on major research advances throughout 2021 and the vital role that our research community continues to play i...
Strengthening the UK clinical research ecosystem
17th December 2021
The UK Clinical Research Recovery, Resilience and Growth Programme (RRG) has published an update detailing the key milestones that have been achieved in the 6 months since the...
-
Ground-breaking COVID-19 antiviral treatment trial opens to recruitment
8th December 2021
A first-of-its-kind clinical trial to investigate the effectiveness of new COVID-19 oral antiviral treatments - which can be safely taken at home - has begun enrolling partici...
Read full article
-
IRAS amendment tool updated to new version
6th December 2021
From Monday 6 December 2021, the amendment tool will indicate that substantial changes to the Investigator Brochure (IB) do not need to be submitted to a NHS Research Eth...
Read full article
-
World first COVID-19 vaccine booster study publishes data
3rd December 2021
Six COVID-19 vaccines are safe and boost immunity for people who have had two doses of AstraZeneca or Pfizer-BioNTech, results from the UK-wide COV-BOOST trial show Th...
Read full article
-
NRS Neuroprogressive and Dementia launch new strategy
2nd December 2021
The new strategy lays out how the Network will involve, engage with, and support people with lived experience of neuroprogressive conditions or dementia. Th...
Read full article
